Advertisement
About one-third of survivors of sepsis or septic shock are readmitted within 30 days

One-Third of Septic Shock Survivors Readmitted

0
Readmitted patients have higher chronic illness burden, prevalence of health care-linked sepsis
Researchers have developed a genetic test to quickly detect enterovirus D68. The researchers published details of the test's techniques online recently in the Journal of Clinical Microbiology.

New Gene Test Speeds Diagnosis of Enterovirus D68

0
Virus sickened more than 1,000 U.S. children last year, 14 deaths reported
About 10 percent of cases where a drug does serious harm are not reported to the U.S. Food and Drug Administration within the required 15-day period

Delays Noted in the Reporting of Serious Patient Harms to FDA

0
Analysis found roughly 10 percent of cases were filed after 15-day deadline passed
Eradication of Helicobacter pylori in asymptomatic adults is associated with a reduction in the incidence of gastric cancer

Review: Eradicating H. pylori Cuts Incidence of Gastric Cancer

0
Reduction in the incidence of gastric cancer with tx of asymptomatic, otherwise healthy individuals
As a result of the increasing popularity of high-deductible health care plans

Expansion of High-Deductible Plans to Impact Physician Care

0
Physicians must be able to balance provision of good clinical care with ability to limit costs
Researchers say they've made preliminary progress toward developing a drug that one day may treat people infected with the Marburg virus

Progress Reported in Treatment of Marburg Virus

0
Researchers found infected monkeys were less likely to die with treatment
A new diagnostic to differentiate between HIV-1 antibodies

FDA Approves Test to Differentiate HIV Viruses

0
Among people two years and older
Technivie (ombitasvir

FDA Approves Technivie for Hepatitis C

0
For people with chronic hepatitis C genotype 4
For contacts of individuals with multidrug-resistant tuberculosis

Fluoroquinolones Halt Multidrug-Resistant-TB in Contacts

0
FQN preventive therapy linked to health system savings and lower mortality versus no therapy
Combination treatments show promise for HIV and hepatitis C virus coinfection

Combo Treatments Promising for HIV-HCV Coinfection

0
Sustained virologic response for ledipasvir and sofosbuvir; and for daclatasvir and sofosbuvir